High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
- 1 July 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Vol. 14 (7), 1080-1083
- https://doi.org/10.1161/01.atv.14.7.1080
Abstract
We determined the prevalence of hyperhomocyst(e)inemia before and 4 hours after a methionine load (3.8 g/m2) in 80 patients (25 mean and 55 women) who had had at least one verified episode of venous thromboembolism before the age of 40 years and in 51 healthy control subjects. No patient had any of the hemostatic abnormalities known to be associated with increased risk of venous thrombosis, and all had normal renal and liver function and no evidence of neoplastic disease. Hyperhomocyst(e)inemia was defined as fasting plasma homocyst(e)ine levels or absolute postload increments of homocyst(e)ine above the normal range. According to these diagnostic criteria, 15 patients (18.8%) and 1 control subject (1.9%) had hyperhomocyst(e)inemia. In 1 of these patients only, hyperhomocyst(e)inemia could be explained by low serum concentrations of vitamin B12 and folates. The family history for venous thromboembolism was positive for 7 of the 15 patients. Family studies, performed for eight kindreds, showed that for more than half of the studied probands the abnormality was inherited. This study indicates that moderate hyperhomocyst(e)inemia is associated with an increased risk of developing venous thromboembolism at a young age and that measurements of fasting and postmethionine plasma homocyst(e)ine levels may be useful in the evaluation of patients with juvenile venous thromboembolism, particularly if their family history suggests the presence of an inherited abnormality.Keywords
This publication has 17 references indexed in Scilit:
- Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosisThrombosis Research, 1993
- Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.Journal of Clinical Investigation, 1993
- Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.Journal of Clinical Investigation, 1993
- Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.Journal of Clinical Investigation, 1993
- Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.Journal of Clinical Investigation, 1991
- Inherited factors in thrombosisBlood Reviews, 1988
- Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.Journal of Clinical Investigation, 1986
- Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.Journal of Clinical Investigation, 1986
- Endothelial cell dysfunction in homocystinuriaEuropean Journal of Clinical Investigation, 1983
- Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.Journal of Clinical Investigation, 1976